Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV

NCT04340388 is registered in ClinicalTrials.gov with Augusta University as lead sponsor.

NCT NCT04340388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04340388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV
Lead sponsor
Augusta University
Phase
Phase 4
Overall status
Completed
Start date
September 17, 2020
Completion date
February 25, 2023
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abnormality of adipose tissue, antiviral drug adverse reaction, body fat disorder, body weight changes, cardiovascular abnormalities, hiv-1-infection, hiv-associated lipodystrophy syndrome, vascular diseases